Ann: Botanix Joins with UQ to Accelerate Development of BTX 1801, page-34

Yes that was the comment that I was referring to and it came from a very good doctor as well. Lip service maybe but reputations are reputations. So this new collaboration I believe is very exciting because of the target markets they wish to focus on.

There are always some sort of big pharma deals going on out there and a recent 95million euro whatever that is in aussie dollar terms between Novartis and a strange company called Galapagos and MorphoSys in the dermatitis market is an example. These folks are working on a more high tech product which I believe is an injectable. Further numbers of this deal suggest if it gets to market then further milestones of eight hundred and fifty million euro are possible. Just tattslotto numbers however legal tasttslotto numbers. In australia there are a few of these expensive drugs such as Stelara which costs the NHS about $4500 per injection every 3 months. It has to be said that Novartis is shooting for immuno-dermatology in its approach as the ultimate pricing of these products is just so high. What BOT is doing in my opinion is taking the disruptor approach. We are one of few using CBD and in my opinion, so far so good without getting bogged down in all the statistical hyperbole. I like a comment i recently read concerning another British biotech with a great name, Crescendo Biologics. Great name indeed . Crescendo are into psoriasis trials and although they are a novel cancer antibody developer, this recent psoriasis tangent is interesting. You have to be a bit creative out there and quite possibly our new queensland uni tie up is just that. Good on Matt anyway folks. So here is the line from - 'Biologics-based therapies are increasingly effective in psoriasis and other skin conditions, but are often associated with treatment-limiting immunosuppresive side effects." From our perspective we know safety and sensitivity is very important and although a lot of dermo companies doing trials use higher tech compounds, the cleanliness of BOTs proprietary items will come to the fore. There is so much of the normal steroidal stuff being sold out there such as advantan and diprosone together with some new ones like elidel. We fit in rather nicely as this disruptor and who knows how far we are going to go but Matt clearly knows how to spread his tentacles. Yes tentacles.

On with the show. I know it is early days but in the future if we suddenly go out and hire someone who has had some major big pharma experience , well you know what that will be all about. Yes Matt has done some deals before but you never know what can be brought to the table.

I keep thinking to myself Acne Dermatitis Skin Infections and Proriasis. Not too shabby at all but it does take time for the market to catch onto all this stuff.